Videos

A clinical pharmacist details how treatment algorithms differ between early-stage and metastatic breast cancer.

Expert perspectives on differentiating between the three CDK4/6 inhibitors available for the treatment of metastatic breast cancer are discussed, highlighting factors that inform treatment selection.

Medical experts examine the current treatment landscape and goals for patients with hepatic encephalopathy, addressing patient outcomes and hospital discharge planning, while also acknowledging that some patients may require rehabilitation or long-term care facilities to sustain remission and optimize their recovery.

Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, delve into the complexities of hepatic encephalopathy, exploring the various risk factors that contribute to its development, such as alcohol-induced cirrhosis, sarcopenia, CNS medications, opioids, and other potential triggers.

Sa’ed Al-Olimat, PharmD, co-founder of the Psychedelic Pharmacists Association, discussed the future of psychedelic medicines and the unique ethical challenges they present.

Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some common challenges pharmacists may be facing when looking to operationalize bispecifics at their facilities.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.

Jonathan Levitt, Esq, discusses legislation and legal action taken to rein in pharmacy benefit managers’ DIR fees.

Scott Soefje, PharmD, BCOP, FCCP, FHOPA, MBA, addresses some of the key steps pharmacists should take when conducting a financial analysis for cancer drugs.

Whitney Lewis, PharmD, BCOP, discusses how the treatment armamentarium for NSCLC has expanded in recent years and the associated cause for this acceleration.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some of the considerations for bispecifics in relation to facility readiness at different sites and among different stakeholders.

James Shehan shares insights on the promising trends shaping the weight loss medication and how changing views of obesity could pave the way for uptake GLP-1s.

Tune into this episode of “Public Health Matters” to learn about Dr. Pauline K. Long and her entrepreneurship journey, as well as how she creates meaningful impacts on patients in marginalized communities and within public health.

Danielle Roman, PharmD, BCOP, discusses how the role of the oncology pharmacist has changed in recent years in optimizing early-stage breast cancer treatment with targeted therapies.

Karen Fancher, PharmD, BCOP, discusses some guiding principles for oncology pharmacists when facing ethical dilemmas and provides some recommendations for navigating those challenges.

Aimee Keegan, PharmD, BCOP, discusses how her institution optimizes patient adherence to CDK4/6 inhibitors, highlighting resources including their in-house specialty pharmacy.

Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors.

Pharmacists can address social determinants to improve patient well-being and treatment.

Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.

In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.

Potential for integration into care and future advancements for gaps in current schizophrenia treatments

Guidance on evaluating contraceptive options for patients with psychiatric conditions

New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.

Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder

Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia

The Librexia program includes 3 concurrent clinical trials, investigating milvexian’s use for ischemic stroke, acute coronary syndrome, and atrial fibrillation

James Shehan discusses the growth of the GLP-1 receptor agonist market for medicated-assisted weight loss.

Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.

The manager of clinical pharmacy at UPMC Health Plan describes the significance of the pharmacist’s role in multiple sclerosis care and when collaborating with other health care providers.